Literature DB >> 15229944

Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naïve patients.

Jasvinder A Singh1, Jose A Pando, John Tomaszewski, H Ralph Schumacher.   

Abstract

OBJECTIVE: To describe the immunohistochemical features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naïve patients.
METHODS: Eight patients presenting with oligoarthritis or polyarthritis, who later met American Rheumatism Association criteria for rheumatoid arthritis (RA), underwent needle synovial biopsies of a knee joint within the first 6 weeks after onset of disease symptoms. Using antibodies to CD3, CD8, L26, CD68, and von Willebrand factor, a detailed quantitative immunohistochemical analysis was done.
RESULTS: CD3+ T lymphocytes, CD8+ T lymphocytes, L26+ B lymphocytes, and CD68+ macrophages were seen in 8/8 (100%), 7/8 (87%), 4/8 (50%), and 6/6 (100%) of synovial biopsies stained with the respective marker. There was a wide variation in number of positive cells between patients. CD3+ and CD8+ T cells were seen predominantly in perivascular areas, less often in a diffuse distribution, and not in aggregates. L26+ B lymphocytes were found in much smaller numbers compared with T lymphocytes. A mean of 67 vessels/mm2 was noted. No lymphoid aggregates were seen. In all cases, infiltration of macrophages and lymphocytes was limited mainly to relatively superficial parts of synovium, i.e., within 1 to 2 high power fields of the surface.
CONCLUSION: An absence of lymphoid aggregates or dramatic vascularity and a predominantly superficial infiltrate consisting mainly of perivascular T cells with few B cells characterized our patients with very early RA of < 6 weeks' duration. Thus, there appear to be some potentially important differences from findings reported in well established disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229944

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  The needle and the damage done.

Authors:  J K Franz; G-R Burmester
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

Review 2.  Patients with suspected rheumatoid arthritis should be referred early to rheumatology.

Authors:  Kimme L Hyrich
Journal:  BMJ       Date:  2008-01-26

Review 3.  Treating very early rheumatoid arthritis.

Authors:  Karim Raza; Caitriona E Buckley; Mike Salmon; Christopher D Buckley
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-10       Impact factor: 4.098

4.  Gene expression profiling of macrophages: implications for an immunosuppressive effect of dissolucytotic gold ions.

Authors:  Oliver Seifert; Andreas Matussek; Florence Sjögren; Robert Geffers; Chris D Anderson
Journal:  J Inflamm (Lond)       Date:  2012-11-09       Impact factor: 4.981

5.  The synovium in rheumatoid arthritis.

Authors:  Carol A Hitchon; Hani S El-Gabalawy
Journal:  Open Rheumatol J       Date:  2011-12-30

6.  Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis.

Authors:  Yoony Y J Gent; Karin Weijers; Carla F M Molthoff; Albert D Windhorst; Marc C Huisman; Desirée E C Smith; Sumith A Kularatne; Gerrit Jansen; Philip S Low; Adriaan A Lammertsma; Conny J van der Laken
Journal:  Arthritis Res Ther       Date:  2013-03-01       Impact factor: 5.156

Review 7.  Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.

Authors:  Manuela Di Franco; Maria Chiara Gerardi; Bruno Lucchino; Fabrizio Conti
Journal:  Core Evid       Date:  2014-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.